Study Complete
Sponsor ID
20020134

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin’s Lymphoma

Sponsor ID
20020134
Clinicaltrials.gov ID
NCT00115193
EUCTIS ID
N/A
EudraCT ID
N/A

Study Details

The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.

Additional Study Details

Phase
Phase 2
Product
pegfilgrastim
Type
Interventional
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment
77
Additional Study Details

Protocol Summary

Primary Outcome Measures

Reduce the duration of neutropenia and incidence of febrile neutropenia.

Timeframe: The primary outcome will be evaluated at the end of the study.

Secondary Outcome Measures

On the same day as chemotherapy as measured by the incidence of hematologic and non-hematologic toxicities, the number of subjects who received planned doses of chemotherapy on time and response rates.

Timeframe: The secondary outcome will be evaluated at the end of the study.

Locations

No locations found.